Tolperisone - Sanochemia

Drug Profile

Tolperisone - Sanochemia

Alternative Names: Agileo; AV-650; Instant release (IR) tolperisone tablets - Sanochemia; SPH-3047; Sustained release tolperisone tablets - Sanochemia; Tolcare; Viveo

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Sanochemia Pharmazeutika
  • Developer Avigen; Sanochemia Pharmazeutika
  • Class Analgesics; Antispasmodics; Antispastics; Muscle relaxants; Propiophenones; Pyridines; Small molecules
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Muscle hypertonia; Muscle spasticity
  • No development reported Spasm

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Spasm in Germany (PO)
  • 09 Mar 2016 Katama Pharmaceuticals announces intention to submit NDA to US FDA in 2019
  • 09 Mar 2016 Katama Pharmaceuticals plans a phase II trial for Muscle spasticity in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top